-
Mashup Score: 7
Our paper with Vinay Prasad is now published in the Journal of Cancer Policy – and it couldn’t be more timely!
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1The Drug Development Letter | Vinay Prasad | Substack - 3 day(s) ago
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases. Click to read The Drug Development Letter, by Vinay Prasad, a Substack publication with thousands of subscribers.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3RANDOMIZED versus REAL-WORLD EVIDENCE ON THE EFFICACY AND TOXICITY OF CHECKPOINT INHIBITORS. - 2 month(s) ago
This is a talk I presented at the ESMO Immuno-Oncology 2024 Congress, recorded live with Vinay Prasad and the VKPrasad Lab team, followed by an engaging Q&A session!
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13Does the clinical value of a drug predict Medicare expenditures? - 2 month(s) ago
In short, the answer is negative, as we found in our study published in the Journal of Cancer Policy. Our analysis also revealed other interesting findings.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Immune Checkpoint Inhibitors: 10-Year Results in Melanoma Are Now Out – Let's Reflect on These Impressive Advances. - 2 month(s) ago
Remarkable advances and remaining questions.
Source: www.drugdevletter.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 6Immune Checkpoint Inhibitors: 10-Year Results in Melanoma Are Now Out – Let's Reflect on These Impressive Advances. - 2 month(s) ago
Remarkable advances and remaining questions.
Source: www.drugdevletter.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1The Drug Development Letter | Vinay Prasad | Substack - 3 month(s) ago
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases. Click to read The Drug Development Letter, by Vinay Prasad, a Substack publication with thousands of subscribers.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1The Drug Development Letter | Vinay Prasad | Substack - 4 month(s) ago
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases. Click to read The Drug Development Letter, by Vinay Prasad, a Substack publication with thousands of subscribers.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Special post-ESMO 2024 edition ! - 4 month(s) ago
Timothee Olivier and I discuss the top ESMO 2024 abstracts!
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Artificial Intelligence in Medicine - My Keynote - 4 month(s) ago
Strengths and Limitations of AI in Healthcare
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet
Adding Adjuvant Drugs From Distinct Breast Cancer Trials https://t.co/hEixyrKyb0 via @Timothee_MD et al @Maherjane